AlzeCure receives US patent for NeuroRestore ACD856

Alze­Cure Phar­ma AB, a phar­ma­ceu­ti­cal com­pa­ny that devel­ops a broad port­fo­lio of small mol­e­cule can­di­date drugs for dis­eases affect­ing the cen­tral ner­vous sys­tem, with projects in both Alzheimer’s dis­ease and pain, today announced that the Unit­ed States Patent Office (USPTO) has issued a patent cov­er­ing ACD856, which is being devel­oped against Alzheimer’s dis­ease and oth­er dis­or­ders with cog­ni­tive impairment.

USPTO has announced that they have now approved the com­pa­ny’s patent appli­ca­tion in the US, which refers to ACD856, the lead­ing drug can­di­date in the Neu­roRe­store plat­form, which is being devel­oped against Alzheimer’s dis­ease. The patent num­ber is US 11,352,332 and the patent is valid until 2039.

ACD856 and oth­er sub­stances in the Neu­roRe­store plat­form stim­u­late sev­er­al impor­tant sig­nal­ing sys­tems and sig­nal­ing mol­e­cules in the brain such as BDNF (Brain Derived Neu­rotroph­ic Fac­tor) and NGF (Nerve Growth Fac­tor), which can lead to improved cog­ni­tion. Pre­vi­ous pre­clin­i­cal stud­ies have shown that Alze­Cure’s drug can­di­dates strength­en com­mu­ni­ca­tion between nerve cells and improve cog­ni­tive abil­i­ty, includ­ing learn­ing and mem­o­ry func­tions. New pre­clin­i­cal results also show poten­tial neu­ro­pro­tec­tive and dis­ease-mod­i­fy­ing effects with these sub­stances. The bio­log­i­cal mech­a­nism behind Neu­roRe­store enables sev­er­al indi­ca­tions, such as Alzheimer’s and Parkin­son’s dis­ease, but also depression.

“We are con­tin­u­ing to build a patent port­fo­lio for our Neu­roRe­store pro­gram. This is an impor­tant step for ACD856, which is in clin­i­cal devel­op­ment against Alzheimer’s,” said Gun­nar Nord­vall, Head of Chem­istry and IP.

“These are very good news and con­sti­tute an impor­tant mile­stone for both the project and the com­pa­ny and fur­ther strength­ens our com­mer­cial oppor­tu­ni­ties for this promis­ing sub­stance, which has just gen­er­at­ed new pos­i­tive clin­i­cal data,” said Mar­tin Jöns­son, CEO.